Eagle Pharmaceuticals, Inc. NASDAQ:EGRX

Founder-led company

Eagle Pharmaceuticals stock price today

$3.18
+2.68
+536%
Financial Health
0
1
2
3
4
5
6
7
8
9

Eagle Pharmaceuticals stock price monthly change

-91.69%
month

Eagle Pharmaceuticals stock price quarterly change

-91.69%
quarter

Eagle Pharmaceuticals stock price yearly change

-90.37%
year

Eagle Pharmaceuticals key metrics

Market Cap
7.12M
Enterprise value
415.45M
P/E
10.67
EV/Sales
1.31
EV/EBITDA
5.74
Price/Sales
1.28
Price/Book
1.74
PEG ratio
0.02
EPS
1.19
Revenue
257.55M
EBITDA
39.32M
Income
15.56M
Revenue Q/Q
-12.80%
Revenue Y/Y
-5.37%
Profit margin
11.26%
Oper. margin
25.57%
Gross margin
70.01%
EBIT margin
25.57%
EBITDA margin
15.27%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Eagle Pharmaceuticals stock price history

Eagle Pharmaceuticals stock forecast

Eagle Pharmaceuticals financial statements

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX): Profit margin
Sep 2022 65.90M -3.51M -5.33%
Dec 2022 60.69M 8.16M 13.45%
Mar 2023 66.30M 5.75M 8.67%
Jun 2023 64.64M 5.16M 7.99%
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX): Debt to assets
Sep 2022 390067000 154.66M 39.65%
Dec 2022 406160000 172.6M 42.5%
Mar 2023 414175000 171.33M 41.37%
Jun 2023 404822000 152.78M 37.74%
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX): Cash Flow
Sep 2022 -13.23M -11.23M 3.29M
Dec 2022 37.55M -9K 2.38M
Mar 2023 -33.51M -12.55M 12.64M
Jun 2023 -126K -6K -6.41M

Eagle Pharmaceuticals alternative data

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX): Employee count
Aug 2023 134
Sep 2023 134
Oct 2023 134
Nov 2023 134
Dec 2023 134
Jan 2024 134
Feb 2024 134
Mar 2024 134
Apr 2024 134
May 2024 134
Jun 2024 134
Jul 2024 134

Eagle Pharmaceuticals other data

78.54% -11.40%
of EGRX is owned by hedge funds
10.08M -1.52M
shares is hold by hedge funds

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX): Insider trades (number of shares)
Period Buy Sel
May 2023 0 60000
Oct 2023 0 20245
Nov 2023 0 21619
Transaction Date Insider Security Shares Price per share Total value Source
Sale
TARRIFF SCOTT director, 10 perc.. Common Stock 10,694 $13.87 $148,326
Sale
TARRIFF SCOTT director, 10 perc.. Common Stock 10,925 $13.82 $150,984
Option
GRAVES MICHAEL director
Common Stock 9,360 $4.94 $46,238
Option
GRAVES MICHAEL director
Stock Option (right to buy) 9,360 $4.94 $46,238
Sale
TARRIFF SCOTT director, 10 perc.. Common Stock 710 $15.11 $10,728
Sale
TARRIFF SCOTT director, 10 perc.. Common Stock 10,024 $14.41 $144,446
Sale
TARRIFF SCOTT director, 10 perc.. Common Stock 9,511 $15.23 $144,853
Sale
TARRIFF SCOTT director, 10 perc.. Common Stock 15,000 $19.98 $299,700
Sale
TARRIFF SCOTT director, 10 perc.. Common Stock 14,800 $21.06 $311,688
Sale
TARRIFF SCOTT director, 10 perc.. Common Stock 200 $21.52 $4,304
Patent
Application
Filling date: 10 May 2022 Issue date: 25 Aug 2022
Application
Filling date: 2 Dec 2021 Issue date: 24 Mar 2022
Application
Filling date: 18 Nov 2021 Issue date: 10 Mar 2022
Application
Filling date: 26 Aug 2021 Issue date: 23 Dec 2021
Grant
Filling date: 8 Apr 2013 Issue date: 23 Nov 2021
Application
Filling date: 19 Jul 2021 Issue date: 11 Nov 2021
Grant
Filling date: 12 Jul 2019 Issue date: 31 Aug 2021
Application
Filling date: 16 Sep 2020 Issue date: 26 Aug 2021
Application
Filling date: 21 May 2019 Issue date: 5 Aug 2021
Application
Filling date: 8 May 2020 Issue date: 15 Apr 2021
Friday, 15 November 2024
globenewswire.com
Tuesday, 22 October 2024
accesswire.com
Tuesday, 8 October 2024
gurufocus.com
Tuesday, 27 August 2024
globenewswire.com
Wednesday, 22 May 2024
globenewswire.com
Monday, 15 April 2024
globenewswire.com
Friday, 12 April 2024
globenewswire.com
Friday, 9 February 2024
accesswire.com
prnewswire.com
accesswire.com
accesswire.com
prnewswire.com
accesswire.com
accesswire.com
Thursday, 8 February 2024
accesswire.com
accesswire.com
prnewswire.com
accesswire.com
businesswire.com
prnewswire.com
accesswire.com
Wednesday, 7 February 2024
prnewswire.com
Tuesday, 6 February 2024
prnewswire.com
prnewswire.com
accesswire.com
Saturday, 3 February 2024
prnewswire.com
accesswire.com
Friday, 2 February 2024
prnewswire.com
accesswire.com
prnewswire.com
  • What's the price of Eagle Pharmaceuticals stock today?

    One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $3.18.

  • When is Eagle Pharmaceuticals's next earnings date?

    Unfortunately, Eagle Pharmaceuticals's (EGRX) next earnings date is currently unknown.

  • Does Eagle Pharmaceuticals pay dividends?

    No, Eagle Pharmaceuticals does not pay dividends.

  • How much money does Eagle Pharmaceuticals make?

    Eagle Pharmaceuticals has a market capitalization of 7.12M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 84.56% to 316.61M US dollars.

  • What is Eagle Pharmaceuticals's stock symbol?

    Eagle Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "EGRX".

  • What is Eagle Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Eagle Pharmaceuticals?

    Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Eagle Pharmaceuticals's key executives?

    Eagle Pharmaceuticals's management team includes the following people:

    • Mr. Scott L. Tarriff Founder, Pres, Chief Executive Officer & Director(age: 65, pay: $1,400,000)
    • Mr. David M. Pernock Executive Vice President of Operations(age: 72, pay: $896,320)
    • Mr. Brian Joseph Cahill Chief Financial Officer(age: 56, pay: $500,240)
  • Is Eagle Pharmaceuticals founder-led company?

    Yes, Eagle Pharmaceuticals is a company led by its founder Mr. Scott L. Tarriff.

  • How many employees does Eagle Pharmaceuticals have?

    As Jul 2024, Eagle Pharmaceuticals employs 134 workers.

  • When Eagle Pharmaceuticals went public?

    Eagle Pharmaceuticals, Inc. is publicly traded company for more then 11 years since IPO on 12 Feb 2014.

  • What is Eagle Pharmaceuticals's official website?

    The official website for Eagle Pharmaceuticals is eagleus.com.

  • Where are Eagle Pharmaceuticals's headquarters?

    Eagle Pharmaceuticals is headquartered at 50 Tice Boulevard, Woodcliff Lake, NJ.

  • How can i contact Eagle Pharmaceuticals?

    Eagle Pharmaceuticals's mailing address is 50 Tice Boulevard, Woodcliff Lake, NJ and company can be reached via phone at +20 13 265300.

Eagle Pharmaceuticals company profile:

Eagle Pharmaceuticals, Inc.

eagleus.com
Exchange:

NASDAQ

Full time employees:

134

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

50 Tice Boulevard
Woodcliff Lake, NJ 07677

CIK: 0000827871
ISIN: US2697961082
CUSIP: 269796108